Montelukast and zafirlukast are cysteinyl leukotriene receptor antagonists indicated to prevent and treat chronic asthma. Leukotrienes are eicosanoid inflammatory mediators derived from arachidonic acid. Neither montelukast nor zafirlukast has a role as rescue medication during an acute asthmatic attack. This activity will highlight the mechanism of action, adverse event profile, and monitoring pertinent for interprofessional team members in managing patients with asthma and related conditions with leukotriene receptor antagonists.
Copyright © 2024, StatPearls Publishing LLC.